



EUROPEAN COMMISSION

Health and Food Safety Directorate General

sante.g.3(2023)332040

Standing Committee on Plants, Animals, Food and Feed

Section *Genetically Modified Food and Feed*

14 December 2022

CIRCABC Link: <https://circabc.europa.eu/ui/group/55b2edd3-069e-40fd-ad4a-8b163f54ff1f/library/e557a381-4cff-4327-9cc7-1651b9fbe726?p=1>

SUMMARY REPORT

A.01 Assessment of genetically modified isolated seed protein from oilseed rape GT73 for food uses, under Regulation (EC) No 1829/2003 (application EFSA- GMO-RX-026/2) – Presentation by EFSA.

EFSA presented the opinion on the application for the placing on the market of genetically modified isolated seed protein from oilseed rape GT73.

One Member State raised a point on the possible need for allergenicity labelling.

A.02 Assessment of genetically modified oilseed rape GT73 for renewal authorisation, under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-026/1) – Presentation by EFSA

EFSA presented the opinion on the renewal of the authorisation for the placing on the market of genetically modified oilseed rape GT73.

One Member State raised a point on the post-market environmental monitoring (PMEM) related to the spillage of an authorised GM oilseed rape.

A.03 Assessment of genetically modified cotton 281-24-236 x 3006-210-23 for renewal authorisation, under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-019) – Presentation by EFSA.

EFSA presented the opinion on the renewal of the authorisation for the placing on the market of genetically modified GM cotton 281-24-236 x 3006-210-23.

No questions were raised by the Member States.

A.04 Assessment of genetically modified maize MON 87429 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2019-161) – Presentation by EFSA.

EFSA presented the opinion on the application for the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87429.

No questions were raised by the Member States.

One Member State provided an update on ongoing work related to teosinte and will share this information with the Commission and the Member States.

A.05 Assessment of genetically modified maize GM maize MON 95379 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2020-170) – Presentation by EFSA.

EFSA presented the opinion on the application for the placing on the market of products containing, consisting of or produced from genetically modified maize MON 95379.

A.06 Assessment of genetically modified maize DP4114 x MON89034 x MON87411 x DAS-40278-9 and its sub-combinations for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2020-171) – Presentation by EFSA.

EFSA presented the opinion on the application for the placing on the market of products containing, consisting of or produced from genetically modified maize DP4114 x MON89034 x MON87411 x DAS-40278-9 and its sub-combinations.

No questions were raised by the Member States.

B.01 Exchange of views and possible opinion of the Committee on a draft Commission Draft Implementing Decision authorising the placing on the market of products containing, consisting of or produced from genetically modified oilseed rape MON 94100, pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council

The draft Decision authorising the placing on the market of products containing, consisting of or produced from genetically modified oilseed rape MON 94100 was presented to the Committee.

One Member State provided comments on the PMEM plan in the context of a recent spillage in a crushing facility concerning an authorized oilseed rape, and raised the question of whether the PMEM for oilseed rape should be updated. This was supported by three Member States. The Commission presented the follow-up to the spillage incident mentioned, and informed Member States that the relevant documents were available to the Committee. It was agreed to discuss the PMEM plan related to all GM oilseed rape authorisations at the next Committee meeting.

Vote taken: no opinion.

Reasons for negative vote or abstention:

- No agreed national position
- Negative public opinion
- Precautionary principle
- Scientific reasons
- Political reasons

Consequently, the Chair informed the Committee that the draft Decision will be submitted to the Appeal Committee.